INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
6.20
+0.17 (+2.82%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.03
Open6.05
Bid6.18 x 400
Ask6.60 x 600
Day's Range5.88 - 6.29
52 Week Range4.10 - 15.02
Volume964,808
Avg. Volume749,541
Market Cap454.563M
Beta1.97
PE Ratio (TTM)N/A
EPS (TTM)-2.57
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.80
Trade prices are not sourced from all markets
  • Capital Cube14 hours ago

    INSYS Therapeutics, Inc. – Value Analysis (NASDAQ:INSY) : December 15, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives INSYS Therapeutics, Inc. a score of 66. Our analysis is based on comparing INSYS Therapeutics, Inc. with the following peers – Heron Therapeutics Inc, TESARO, Inc., BioDelivery Sciences International, Inc., Fennec Pharmaceuticals Inc., Depomed, Inc., Mylan N.V., Merck & Co., Inc., AcelRx Pharmaceuticals, Inc., GW Pharmaceuticals PLC ... Read more (Read more...)

  • INSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : December 14, 2017
    Capital Cube2 days ago

    INSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : December 14, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for INSYS Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • 3 Top Stocks Under $10
    Motley Fool6 days ago

    3 Top Stocks Under $10

    Hint: Look to the biotech industry for the best bang for the buck.

  • Investopedia7 days ago

    Pot Stock Winners of the Week

    Canadian cannabis-related companies continue to do well again this week.

  • INSYS Therapeutics, Inc.: Gathering momentum, can it sustain its performance?
    Capital Cube8 days ago

    INSYS Therapeutics, Inc.: Gathering momentum, can it sustain its performance?

    Categories: Yahoo FinanceINSYS Therapeutics, Inc. relative valuation is NEUTRAL and it has a fundamental analysis score of 66. Our analysis is based on comparing INSYS Therapeutics, Inc. with the following peers – Heron Therapeutics Inc, TESARO, Inc., BioDelivery Sciences International, Inc., Fennec Pharmaceuticals Inc., Depomed, Inc., Mylan N.V., Merck & Co., Inc., AcelRx Pharmaceuticals, Inc., GW Pharmaceuticals ... Read more (Read more...)

  • GlobeNewswire9 days ago

    INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis

    PHOENIX, Dec. 07, 2017-- INSYS Therapeutics, Inc., announced today that it has started a proof-of-concept study of two formulations of epinephrine nasal spray for the treatment of anaphylaxis, or severe ...

  • GlobeNewswire10 days ago

    FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics

    PHOENIX, Dec. 06, 2017-- INSYS Therapeutics, Inc., announced today that its New Drug Application for a novel formulation of buprenorphine as a sublingual spray for the management of moderate-to-severe ...

  • True Leaf Seeks to Raise Capital as It Prepares to Enter into the Booming Canadian Marijuana Market
    Insider Monkey11 days ago

    True Leaf Seeks to Raise Capital as It Prepares to Enter into the Booming Canadian Marijuana Market

    Canada is undoubtedly one of the greatest countries on earth. They’ve got universal healthcare, beautiful scenery, a whole region that speaks French and an awesome prime-minister. Now, Canada is about to reach a new milestone that would make it even better, the legalization of cannabis. Earlier this year, a bill was introduced to Canadian Parliament […]

  • Investopedia12 days ago

    Top 4 Marijuana Stocks to Watch

    These four stocks are top picks that capitalize on the marijuana industry.

  • Reuters18 days ago

    Billionaire Insys founder can remove ankle monitor -judge

    The billionaire founder of Insys Therapeutics Inc, charged with engaging in a scheme to bribe doctors to prescribe an opioid, won the lifting of a requirement that he wear a GPS-enabled ankle monitor on Monday, which he said interfered with jogging. While federal prosecutors had argued that John Kapoor's vast wealth made him a flight risk, U.S. Magistrate Judge Jennifer Boal in Boston said she had seen no evidence that he had any intention to flee. Boal said it appeared Kapoor had for years known he was under investigation, yet never tried to flee the country.

  • Associated Press18 days ago

    Founder charged in opioid scheme can remove GPS monitoring

    BOSTON (AP) — The founder of a pharmaceutical company charged with leading a nationwide conspiracy to bribe doctors to prescribe an opioid pain medication has won his bid to remove his electronic monitoring bracelet.

  • GlobeNewswire19 days ago

    INSYS Therapeutics, Inc. to Participate in the 29th Annual Piper Jaffray Healthcare Conference

    PHOENIX, Nov. 27, 2017-- INSYS Therapeutics, Inc. announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will participate in the 29 th Annual ...

  • Bloomberg29 days ago

    Insys's Kapoor ‘Tightly Controlled’ Bribe Scheme, U.S. Says

    Billionaire John Kapoor “tightly controlled’’ a scheme to illegally pay doctors to help boost sales of his company’s opioid-based painkiller and attended a meeting where two physicians were offered bribes, ...

  • Drug firm founder pleads not guilty to opioid bribe scheme
    Associated Presslast month

    Drug firm founder pleads not guilty to opioid bribe scheme

    BOSTON (AP) — A pharmaceutical company founder accused of leading a conspiracy to bribe doctors to prescribe a powerful opioid pain medication will fight the charges against him and believes he will be vindicated, his attorney said Thursday.

  • Reuterslast month

    Billionaire founder of Insys pleads not guilty to opioid bribe scheme

    The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty on Thursday to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray to treat pain in cancer patients. John Kapoor, who stepped down as Insys' chief executive officer and chairman in January but remains its majority shareholder, entered his plea in Boston federal court to charges of conspiracy to commit racketeering, mail fraud and wire fraud. "He doesn't believe it's a strong case," Brian Kelly, Kapoor's lawyer, said.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of INSY earnings conference call or presentation 2-Nov-17 12:30pm GMT

    Q3 2017 INSYS Therapeutics Inc Earnings Call

  • Investopedialast month

    Top 4 Marijuana Stocks to Watch

    These four stocks are top picks that capitalize on the marijuana industry.

  • Why This Marijuana Stock Imploded 42% in October
    Motley Foollast month

    Why This Marijuana Stock Imploded 42% in October

    It's been nothing but bad news lately for this medical marijuana company. Can it get back on track?

  • Why This Marijuana Stock Didn't Sink Despite a Huge Earnings Miss
    Motley Foollast month

    Why This Marijuana Stock Didn't Sink Despite a Huge Earnings Miss

    There's more to the story with this cannabinoid-focused biotech's atrocious third-quarter results.

  • Insys posts loss after founder charged in U.S. opioid bribe case
    Reuterslast month

    Insys posts loss after founder charged in U.S. opioid bribe case

    Insys Therapeutics posted a bigger-than-expected quarterly loss on Thursday due to soft demand for its flagship product Subsys, an opioid cancer pain medication at the center of a federal probe of the company. Last week, John Kapoor, Insys' billionaire founder and majority shareholder, was arrested on charges that he participated in a scheme to bribe doctors to prescribe Subsys. Kapoor resigned from the company's board on Sunday.

  • The Wall Street Journallast month

    [$$] Insys Therapeutics Misses Estimates, Sets Aside Litigation Funds

    Insys Therapeutics missed analysts’ estimates in its latest quarter and set aside roughly $150 million to cover potential settlement costs, following news that its co-founder and former CEO had been charged ...

  • Reuterslast month

    Insys posts bigger loss amid bribery probe of founder

    Insys's billionaire founder John Kapoor was arrested on charges that he participated in a scheme to bribe doctors to prescribe Subsys. The company said on Sunday it recorded $150 million as its "best estimate of the minimum liability" to settle a U.S. Department of Justice investigation into Subsys.

  • Associated Presslast month

    Insys Therapeutics reports 3Q loss

    On a per-share basis, the Chandler, Arizona-based company said it had a loss of $2.30. Losses, adjusted for non-recurring costs and stock option expense, came to 21 cents per share. The results did not ...

  • ACCESSWIRElast month

    Insys Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Insys Therapeutics, Inc. (NASDAQ: INSY ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 8:30 AM Eastern ...

  • Reuterslast month

    Insys Therapeutics posts net loss in third quarter

    Insys Therapeutics on Thursday reported a net loss for the third quarter, compared to a year-ago profit, amid an investigation of the U.S. drugmaker's founder on charges of bribery. The company reported a net loss of $166.3 million or $2.30 per share in the quarter ended Sept. 30, compared to a net income of $2.9 million or 4 cents per share, a year earlier. Insys recorded a $150 million charge in the latest quarter related to an ongoing federal investigation into its opioid painkiller, Subsys.